ARMATA PHARMACEUTICALS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.76 USD | +9.06% |
|
+3.56% | -14.81% |
| Mar. 21 | Earnings Flash (ARMP) ARMATA PHARMACEUTICALS Reports Q4 Revenue $1.5M | MT |
| Mar. 21 | Armata Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Chart calendar Armata Pharmaceuticals, Inc.
c1d60a9e0b3003b.rnoVpvKjkOcqhQ7AXzXHRhwr3nzPG0qxvbruCO4ztoY.yj9t573v54tc9WaEKF2YcnlPpBKgUTCJ1NHYTooL17bJJUKSuI7liULMfQ~d83de35ad58d950384a3b3796f76513e
Upcoming events on Armata Pharmaceuticals, Inc.
Past events on Armata Pharmaceuticals, Inc.
| 2024-03-21 04:05 pm | Q4 2023 Earnings Release |
| 2024-02-28 12:00 pm | Bacteriophage Therapy Summit |
| 2023-11-14 04:00 pm | Q3 2023 Earnings Release |
| 2023-11-03 05:00 pm | North American Cystic Fibrosis Conference ( |
| 2023-10-25 09:10 am | Phage Futures: Global Digital Summit |
| 2023-09-26 02:45 pm | Cantor Global Healthcare Conference |
| 2023-09-13 | Annual General Meeting |
| 2023-08-14 07:00 am | Q2 2023 Earnings Release |
| 2023-06-02 04:50 pm | World Targeting Phage Therapy Conference |
| 2023-05-11 04:05 pm | Q1 2023 Earnings Release |
| 2023-03-16 04:10 pm | Q4 2022 Earnings Release |
| 2022-11-30 10:00 am | H.C. Wainwright Investor Conference |
| 2022-11-15 | Annual General Meeting |
| 2022-11-09 04:15 pm | Q3 2022 Earnings Release |
| 2022-08-11 04:05 pm | Interim 2022 Earnings Release |
| 2022-05-12 04:17 pm | Q1 2022 Earnings Release |
| 2022-03-29 | Extraordinary Shareholders Meeting |
| 2022-03-17 04:05 pm | FY 2021 Earnings Release |
| 2022-03-01 10:00 am | Chardan Metagenomics and Microbiome Medicines Summit |
| 2022-02-23 06:30 pm | BioCom California Global Life Science Partnering Conference |
Annual results
| Fiscal Period | December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 0,00 0,00 - | 0,82 0,51 59.85% | 4,47 4,46 0.37% | 5,51 6,13 -10.11% | 4,53 3,87 17.01% | 4,64 |
|
EBITDA Million USD | Released Forecast Spread | -18,4 -22,0 16.36% | -20,5 -20,9 2.04% | -22,7 -26,3 13.87% | -36,1 -35,5 -1.56% | -39,9 -42,5 6.08% | -47,2 |
|
EBIT Million USD | Released Forecast Spread | -19,8 -22,0 10.14% | -21,6 -20,5 -5.25% | -23,8 -24,9 4.17% | -36,9 -37,4 1.33% | -40,9 -44,9 8.85% | -46,7 |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -19,5 -21,0 7.28% | -22,2 -21,0 -5.4% | -23,2 -24,2 4.51% | -36,9 -36,6 -0.91% | -69,0 -62,0 -11.39% | -49,3 |
|
Net income Million USD | Released Forecast Spread | -19,5 -21,0 7.28% | -22,2 -21,0 -5.4% | -23,2 -24,2 4.51% | -36,9 -36,6 -0.91% | -69,0 -62,0 -11.39% | -49,3 |
|
EPS USD | Released Forecast Spread | -2,49 -2,01 -24.19% | -1,35 -1,26 -6.93% | -0,96 -1,01 4.95% | -1,08 -1,07 -1.41% | -1,91 -1,71 -12.02% | -1,34 |
| Announcement Date | 19/03/20 | 18/03/21 | 17/03/22 | 16/03/23 | 21/03/24 | - |
Quarterly results
| Fiscal Period | December | 2020 S1 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 0,03 1,50 -98% | 0,99 0,98 0.49% | 1,24 0,98 25.55% | 1,88 1,11 69.41% | 1,34 1,66 -19.37% | 1,05 1,67 -37.03% | 0,80 1,78 -55.26% | 0,98 1,81 -45.84% | 1,23 0,95 28.34% | 1,53 0,86 77.67% | 1,14 | 1,15 | 1,17 | 1,19 | 0,00 |
|
EBITDA Million USD | Released Forecast Spread | -5,77 -8,50 32.12% | -8,55 | -8,40 -10,0 16.03% | -10,1 -8,90 -13.3% | -11,1 -10,4 -6.88% | -9,40 -11,5 18.25% | -10,1 -11,6 12.8% | -9,29 -11,2 17.09% | -10,2 | -11,1 | -12,1 | -13,8 | |||
|
EBIT Million USD | Released Forecast Spread | -9,51 -8,40 -13.21% | -6,05 -6,36 4.99% | -8,78 -6,84 -28.33% | -9,22 -7,15 -28.93% | -8,62 -10,3 15.96% | -10,3 -11,1 6.71% | -11,3 -12,9 12.36% | -9,63 -14,4 32.92% | -10,3 -10,5 1.94% | -9,58 -11,5 16.37% | -10,9 | -11,4 | -11,7 | -12,1 | -12,2 |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -9,79 -8,50 -15.18% | -6,05 -7,14 15.35% | -8,77 -6,57 -33.57% | -9,22 -8,32 -10.7% | -8,61 -10,1 14.96% | -10,3 -9,98 -3.32% | -14,5 -11,5 -25.53% | -3,55 -13,4 73.57% | -31,2 -11,3 -175.6% | -19,8 -12,8 -55.24% | -11,2 | -11,9 | -12,6 | -13,6 | -13,7 |
|
Net income Million USD | Released Forecast Spread | -9,79 -8,50 -15.18% | -6,05 -7,14 15.35% | -8,77 -6,57 -33.57% | -9,22 -8,32 -10.7% | -8,61 -10,1 14.96% | -10,3 -9,98 -3.32% | -14,5 -11,5 -25.53% | -3,55 -13,4 73.57% | -31,2 -11,3 -175.6% | -19,8 -12,8 -55.24% | -11,2 | -11,9 | -12,6 | -13,6 | -13,7 |
|
EPS USD | Released Forecast Spread | -0,68 -0,34 -100% | -0,23 -0,28 16.87% | -0,30 -0,21 -42.86% | -0,26 -0,23 -13.04% | -0,24 -0,28 12.73% | -0,29 -0,28 -3.57% | -0,40 -0,32 -25% | -0,10 -0,38 73.33% | -0,86 -0,31 -177.42% | -0,55 -0,35 -57.14% | -0,31 | -0,32 | -0,34 | -0,36 | -0,31 |
| Announcement Date | 13/08/20 | 17/03/22 | 12/05/22 | 11/08/22 | 09/11/22 | 16/03/23 | 11/05/23 | 14/08/23 | 14/11/23 | 21/03/24 | - | - | - | - | - |
More events
Past sector events for Armata Pharmaceuticals, Inc.
| 2024-04-26 | GEMPHARMATECH CO., LTD.: Q1 2024 Earnings Release |
| 2024-04-26 | GEMPHARMATECH CO., LTD.: Q4 2023 Earnings Release |
| 2024-04-26 01:00 am | BB BIOTECH AG: Q1 2024 Earnings Release |
| 2024-04-25 | BIDE PHARMATECH CO., LTD.: Q4 2023 Earnings Release |
| 2024-04-25 | PHARMARESOURCES (SHANGHAI) CO., LTD.: Q1 2024 Earnings Release |
| 2024-04-25 | HINOVA PHARMACEUTICALS INC.: Q1 2024 Earnings Release (Projected) |
| 2024-04-25 | BEIJING SUN-NOVO PHARMACEUTICAL RESEARCH CO., LTD.: Q4 2023 Earnings Release |
| 2024-04-25 | CHEMPARTNER PHARMATECH CO., LTD.: Q4 2023 Earnings Release |
| 2024-04-25 07:00 am | MORPHIC HOLDING, INC.: Q1 2024 Earnings Release |
| 2024-04-25 02:00 am | PURETECH HEALTH PLC: Q4 2023 Earnings Release |
Net sales - Quarter - Rate of surprise
Quarterly earnings - Rate of surprise
Net sales - Annual - Rate of surprise
Annual profits - Rate of surprise
- Stock Market
- Equities
- ARMP Stock
- Calendar Armata Pharmaceuticals, Inc.
